(Q36909336)

17 August 2017

1 reference

title

The role of cytochrome P450 in antiretroviral drug interactions (English)

1 reference

17 August 2017

main subject

anti-retroviral agent

0 references

author name string

Andrew Walubo

series ordinal

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

17 August 2017

published in

1 reference

17 August 2017

volume

3

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

583-598

1 reference

Drug interactions between antiretroviral drugs and comedicated agents

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Indinavir and rifabutin drug interactions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Rosuvastatin-warfarin drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between ritonavir and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Cations in the didanosine tablet reduce ciprofloxacin bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug interactions of HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug interactions with antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Probable interaction between efavirenz and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetics of saquinavir co-administered with cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Fatal interaction between ritonavir and MDMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Decreased methadone effect after ritonavir initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Depression in people living with HIV/AIDS attending primary care and outpatient clinics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Significant interactions with new antiretrovirals and psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug interaction between St John's wort and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

The effect of garlic supplements on the pharmacokinetics of saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Drug points: severe ergotism associated with interaction between ritonavir and ergotamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Need for increased dose of warfarin in HIV patients taking nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Potential interaction involving warfarin and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Cytochrome P450 3A4 activity after surgical stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Therapeutic drug monitoring of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

Efavirenz decreases methadone blood concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.4.583

21 January 2018

Identifiers

DOI

10.1517/17425255.3.4.583

1 reference

17 August 2017

1 reference